Table 2.
Prevalence of any and potent anticholinergic use in CFAS I and CFAS II, by age, sex, cognition and disability
| Any anticholinergic use | Potent anticholinergic use | |||||||
|---|---|---|---|---|---|---|---|---|
| Population | Prevalence % (95% CI) | Adjusted OR for CFAS II vs CFAS Ia | Prevalence % (95% CI) | Adjusted OR for CFAS II vs CFAS Ia | ||||
| CFAS I | CFAS II | OR (95% CI) | pb | CFAS I | CFAS II | OR (95% CI) | pb | |
| Overall | 49.6 (48.4, 50.7) | 64.3 (63.2, 65.4) | 1.25 (1.17, 1.34) | < 0.001 | 5.7 (5.2, 6.3) | 9.9 (9.3, 10.7) | 1.90 (1.67, 2.16) | < 0.001 |
| By sex | ||||||||
| Male | 46.7 (44.9, 48.6) | 61.3 (59.6, 62.9) | 1.00 | 0.06 | 3.6 (3.0, 4.4) | 6.4 (5.6,7.3) | 1.00 | 0.59 |
| Female | 51.3 (49.8, 52.8) | 66.7 (65.2, 68.2) | 1.14 (0.99, 1.30) | 7.0 (6.3, 7.8) | 12.8 (11.7,13.9) | 1.08 (0.82, 1.43) | ||
| By age, years | ||||||||
| 64–69 | 44.4 (42.2,46.6) | 53.5 (51.2,55.7) | 1.00 | < 0.001 | 5.2 (4.3,6.3) | 8.0 (6.8,9.5) | 1.00 | 0.49 |
| 70–74 | 48.2 (45.9,50.6) | 62.9 (60.7,65.1) | 1.33 (1.11, 1.60) | 5.9 (4.9,7.1) | 9.9 (8.6,11.4) | 1.11 (0.76, 1.60) | ||
| 75–79 | 52.8 (50.4,55.2) | 68.8 (66.4,71.0) | 1.41 (1.17, 1.71) | 6.0 (4.9,7.2) | 11.3 (9.7,13.0) | 1.28 (0.88, 1.86) | ||
| 80–84 | 54.3 (51.5,57.0) | 73.0 (70.4,75.5) | 1.48 (1.20, 1.82) | 6.8 (5.5,8.3) | 11.0 (9.3,12.9) | 1.09 (0.73, 1.62) | ||
| 85–89 | 53.8 (49.6,58.0) | 72.1 (68.5,75.5) | 1.58 (1.21, 2.07) | 5.3 (3.7,7.5) | 11.8 (9.5,14.6) | 1.59 (0.95, 2.69) | ||
| 90+ | 50.7 (43.5,57.8) | 75.5 (68.9,81.1) | 2.10 (1.36, 3.22) | 4.1 (2.0,8.0) | 9.0 (5.9,13.6) | 1.54 (0.63, 3.75) | ||
| By cognition | ||||||||
| MMSE ≤21 | 53.3 (49.0, 57.6) | 71.5 (65.0, 77.1) | 1.00 | 0.02 | 11.2 (8.6,14.4) | 16.5 (12.0, 22.3) | 1.00 | 0.83 |
| MMSE 22–25 | 52.7 (50.2, 55.1) | 69.9 (67.1, 72.6) | 0.94 (0.70, 1.25) | 6.7 (5.6,8.1) | 13.4 (11.4,15.6) | 1.10 (0.71, 1.70) | ||
| MMSE 26–30 | 48.6 (47.0, 50.2) | 62.8 (61.5, 64.1) | 0.76 (0.59, 0.99) | 4.5 (3.9,5.2) | 8.4 (7.7,9.2) | 1.00 (0.68, 1.49) | ||
| By disability | ||||||||
| No impairment | 42.4 (40.8,44.0) | 56.9 (55.4,58.5) | 1.00 | 0.27 | 3.8 (3.3, 4.5) | 6.3 (5.6, 7.1) | 1.00 | 0.05 |
| IADL impairment | 67.1 (64.0,70.0) | 80.4 (78.1,82.5) | 1.13 (0.93, 1.36) | 6.8 (5.4, 8.7) | 15.8 (13.8, 18.0) | 1.46 (1.04, 2.04) | ||
| ADL impairment | 71.1 (67.7,74.3) | 85.4 (82.3,88.1) | 1.15 (0.92, 1.43) | 15.8 (13.1,18.9) | 20.8 (17.6, 24.5) | 0.95 (0.70, 1.29) | ||
Weighted for nonresponse and standardised by the UK 2011 age population, missing cases excluded
Abbreviations: CFAS Cognitive Function and Ageing Studies, CI confidence interval, MMSE Mini-Mental State Examination, ADL activities of daily living, IADL instrumental activities of daily living
aAdjusted for age, sex and centre
bGlobal test for the interaction between the covariate and difference in prevalence between CFAS I and CFAS II